At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CRS Carpenter Technology
Post-Mkt 12-11 16:34:47 EST
321.95
+17.35
+5.70%
盘后327.73
+5.78+1.80%
16:30 EST
High323.57Low296.00Vol1.44M
Open303.00D1 Closing304.60Amplitude9.05%
Mkt Cap16.04BTradable Cap15.61BTotal Shares49.82M
T/O453.66MT/O Rate2.96%Tradable Shares48.50M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO
GlobeNewswire  ·  12-11 05:30
NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO
IPO Preview | Can Shima Pharma Win Market Favor in the Billion-Dollar TCE Oncology Therapy Blue Ocean?
Stock News  ·  12-09 13:18
IPO Preview | Can Shima Pharma Win Market Favor in the Billion-Dollar TCE Oncology Therapy Blue Ocean?
Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)
GlobeNewswire  ·  12-09
Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)
Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025
GlobeNewswire  ·  12-08
Autolus Therapeutics Presents Initial Clinical Data in Pediatric r/r B-ALL Patients and Other Oncology Data at the American Society of Hematology (ASH) Annual Meeting 2025
Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)
GlobeNewswire  ·  12-06
Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)
XPOVIO® Approved in Hong Kong for Two Additional Indications in Multiple Myeloma and Diffuse Large B-Cell Lymphoma
prnewswire  ·  12-03
XPOVIO® Approved in Hong Kong for Two Additional Indications in Multiple Myeloma and Diffuse Large B-Cell Lymphoma
Antengene Announces IND Approval in China for Phase Ib/II Study of ATG-022 (CLDN18.2 ADC) in Combination with KEYTRUDA® (Pembrolizumab) ± Chemotherapy
prnewswire  ·  12-02
Antengene Announces IND Approval in China for Phase Ib/II Study of ATG-022 (CLDN18.2 ADC) in Combination with KEYTRUDA® (Pembrolizumab) ± Chemotherapy
Elizabeth A. Socci, VP and Chief Accounting Officer, Reports Disposal of Carpenter Technology Corporation Common Shares
Reuters  ·  12-02
Elizabeth A. Socci, VP and Chief Accounting Officer, Reports Disposal of Carpenter Technology Corporation Common Shares
Inaticabtagene Autoleucel (YORWIDATM) New Drug Application for Lymphoma Approved, China's innovative CAR-T Enters a New Era of Dual Indications
prnewswire  ·  11-28
Inaticabtagene Autoleucel (YORWIDATM) New Drug Application for Lymphoma Approved, China's innovative CAR-T Enters a New Era of Dual Indications
$700 Million Refinancing Could Be A Game Changer For Carpenter Technology (CRS)
Simply Wall St.  ·  11-27
$700 Million Refinancing Could Be A Game Changer For Carpenter Technology (CRS)
Carpenter Technology Closes $700 Million Senior Notes Offering
MT Newswires Live  ·  11-21
Carpenter Technology Closes $700 Million Senior Notes Offering
BRIEF-Carpenter Technology Corp On Nov 20, Co And Others Entered Into Amendment And Restatement Of Credit Facility
Reuters  ·  11-21
BRIEF-Carpenter Technology Corp On Nov 20, Co And Others Entered Into Amendment And Restatement Of Credit Facility
Carpenter Technology Corp - Amendment Increases Revolving Commitments to $500 Mln - SEC Filing
THOMSON REUTERS  ·  11-21
Carpenter Technology Corp - Amendment Increases Revolving Commitments to $500 Mln - SEC Filing
Carpenter Technology Corp: on Nov 20, Co and Others Entered Into Amendment and Restatement of Credit Facility
THOMSON REUTERS  ·  11-21
Carpenter Technology Corp: on Nov 20, Co and Others Entered Into Amendment and Restatement of Credit Facility
Press Release: Carpenter Technology Corporation Announces Closing of $700.0 Million Private Offering of 5.625% Senior Notes Due 2034 and Amendment of Credit Agreement
Dow Jones  ·  11-21
Press Release: Carpenter Technology Corporation Announces Closing of $700.0 Million Private Offering of 5.625% Senior Notes Due 2034 and Amendment of Credit Agreement
PeproMene Bio's PMB-CT01 BAFFR-CAR T Data Selected for Two Oral Presentations at 67th ASH 2025 Annual Meeting
prnewswire  ·  11-20
PeproMene Bio's PMB-CT01 BAFFR-CAR T Data Selected for Two Oral Presentations at 67th ASH 2025 Annual Meeting
Antengene Hosts 2025 R&D Day Showcasing Encouraging Clinical Data and Solid Progress with Investigational Programs
prnewswire  ·  11-20
Antengene Hosts 2025 R&D Day Showcasing Encouraging Clinical Data and Solid Progress with Investigational Programs
Carpenter Technology Corporation Announces Pricing Of $700.0 Million Private Offering Of 5.625% Senior Notes Due 2034
Reuters  ·  11-20
Carpenter Technology Corporation Announces Pricing Of $700.0 Million Private Offering Of 5.625% Senior Notes Due 2034
Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma
GlobeNewswire  ·  11-19
Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma
Should Carpenter Technology’s (CRS) $700 Million Debt Refinance Reshape Its Financial Flexibility?
Simply Wall St.  ·  11-18
Should Carpenter Technology’s (CRS) $700 Million Debt Refinance Reshape Its Financial Flexibility?

Introduction

Company Name.
Carpenter Technology
Affiliated Markets:
NYSE
Listing Date:
--
Main Business:
Carpenter Technology Corporation engages in the manufacture, fabrication, and distribution of specialty metals in the United States, Europe, the Asia Pacific, Mexico, Canada, and internationally. It operates in two segments, Specialty Alloys Operations and Performance Engineered Products. The company offers specialty alloys, including titanium alloys, powder metals, stainless steels, alloy steels, and tool steels, as well as additives, and metal powders and parts. It serves aerospace, defense, medical, transportation, energy, industrial, and consumer markets. The company was founded in 1889 and is headquartered in Philadelphia, Pennsylvania.
Issue price:
--